SLC12A3
Solute carrier family 12 member 3
As of the edition of 20 October 2026, SLC12A3 (solute carrier family 12 member 3, UniProt P55017) has 13 drugs tested at it and 27 companies on the list, 0 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P55017
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 12
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Hormones; Nervous system; Immune system; Lungs and airways
- Registered trials of its drugs
- 342
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Hydrochlorothiazide | Marketed | Phase 4 | none listed |
| Chlorthalidone | Marketed | Phase 4 | none listed |
| Indapamide | Marketed | Phase 4 | none listed |
| Metolazone | Marketed | Phase 4 | none listed |
| Chlorothiazide | Marketed | Phase 4 | none listed |
| Bendroflumethiazide | Marketed | Phase 4 | none listed |
| Hydroflumethiazide | Marketed | No phase stated | none listed |
| Benzthiazide | Marketed | No phase stated | none listed |
| Cyclothiazide | Marketed | No phase stated | none listed |
| Methyclothiazide | Marketed | No phase stated | none listed |
| Polythiazide | Marketed | No phase stated | none listed |
| Quinethazone | Marketed | No phase stated | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 7 |
| Engaged | 3 |
| Undetermined | 17 |
| Total on the list | 27 |
The other 24 companies at SLC12A3
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at SLC12A3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.